Neurology Specific Literature Search   
 
[home][thesaurus]
    

Enter your terms
above and click
the 'Search' button.
Showing articles 0 to 45 of 45

Filter Applied: gammaglobulin therapy,intravenous (Click to remove)

Intravenous Immunoglobulin Treatment of Neurological Disease
JNNP 60:359-361, Otten,A.,et al, 1996

Neuromyelitis Optica Spectrum Disorder
NEJM 387:631-639, Wingerchuk, D.M. & Lucchinetti, C.F., 2022

Myasthenic Crisis Demanding Mechanical Ventilation
Neurol 94:e299-e313, Neumann, B.,et al, 2020

Guillain-Barre Syndrome Associated with JEV Infection
NEJM 383:1188-1190, Wang, G.,et al, 2020

Acute Onset of Diplopia in Pregnancy
Neurol 91:e180-e184, Munro, Z. & Fernandez, D., 2018

A 35-year-old Woman with Diplopia, Ataxia, and Altered Mental Status
Neurol 91:e1942-e1946, Bauer, Z.,et al, 2018

Autoimmune Encephalitides: A Broadening Field of Treatable Conditions
Neurologist 22:1-13, Kalman, B., 2017

Clinical Pathologic Conference, West Nile Virus Encephalitis
NEJM 377:1878-1886, Case 34-2017, 2017

International Consensus Guidance for Management of Myasthenia Gravis
Neurol 87:419-425, Sanders, D.B.,et al, 2016

Myasthenia Gravis
NEJM 375:2570-2581, Gilhus, N.E.,et al, 2016

Utility of an Immunotherapy Trial in Evaluating Patients with Presumed Autoimmune Epilepsy
Neurol 82:1578-1586, Toledano, M.,et al, 2014

Paraparetic Guillain-Barre Syndrome
Neurol 82:1984-1989, Van Den Berg, B.,et al, 2014

Clinicopathologic Conference, Acute Infectious Mononucleosis due to Epstein-Barr Virus Infection, Complicated by Acute Otitis Media and Postinfectious Cerebellitis
NEJM 369:1253-1261, Case 30-2013, 2013

Stiff-Man Syndrome and Variants
Arch Neurol 69:230-238, McKeon,A.,et al, 2012

Evidence-based Guideline: Intravenous Immunoglobulin in the Treatment of Neuromascular Disorders
Neurol 78:1009-1015, Patwa,H.S.,et al, 2012

Autoimmune Epilepsy
Arch Neurol 69:582-593,565, Quek, A.M.L.,et al, 2012

Guillain-Barre Syndrome
NEJM 366:2294-2304, Yuki, N. & Hartung, H.P., 2012

Immune Reconstitution Inflammatory Syndrome in Natalizumab-Associated PML
Neurol 77:1061-1067,1033, Tan, I.L.,et al, 2011

Diagnosis and Management of the Antiphospholipid Syndrome
BMJ 340:1125-1132, Cohen,D., et al, 2010

Relapse Management in Multiple Sclerosis
The Neurologist 15:1-5, Thrower,B.W., 2009

Voltage-gated Potassium Channel-associated Limbic Encepahlitis in the West of Scotland:Case Reports and Literature Review
Scott Med J 54:27-31, Reid,J.M.,et al, 2009

Acute Limbic Encephalitis and Glutamic Acid Decarboxylase Antibodies:A Reality?
J Neurosci 287:69-71, Blanc,F.,et al, 2009

Long-Term Course of Demyelinating Neuropathies Occurring During Tumor Necrosis Factor-a-Blocker Therapy
JAMA Neurol 66:490-497, Lozeron, P.,et al, 2009

Guillain-Barre Syndrome
BMJ 337:227-231, Winer,J.B., 2008

Intravenous Immunoglobulin Therapy for Miller Fisher Syndrome
Neurol 68:1144-1146, Mori,M.,et al, 2007

Classifications and Treatment Responses in Chronic Immune-Mediated Demyelinating Polyneuropathy
Neurol 68:1622-1629, Tackenberg,B.,et al, 2007

Multifocal Motor Neuropathy: The Diagnostic Spectrum and Response to Treatment
Neurol 69:1680-1687, Slee,M.,et al, 2007

Clinical and Electrophysiologic Correlates of IVIg Responsiveness in CIDP
Neurol 64:1471-1475, Iijima,M.,et al, 2005

Guillain-Barre Syndrome
Lancet 366:1653-1666, Hughes,R.C. &Comblath,D.R., 2005

Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004

Potassium Channel Antibody-Associated Encephalopathy: A Potentially Immunotherapy-Responsive Form of Limbic Encepahlitis
Brain 127:701-712, Vincent,A.,et al, 2004

Practice Parameter:Immunotherapy for Guillain-Barre Syndrome, Report of the Quality Standards Subcommittee of the American Academy of Neurology
Neurol 61:736-740, Hughes,R.A.C.,et al, 2003

Disease Modifying Therapies in Multiple Sclerosis
Neurol 58:169-178, Goodin,D.S.,et al, 2002

Course and Treatment of Myasthenia Gravis During Pregnancy
Neurol 52:447-452, Batocchi,A.P.,et al, 1999

Outcome in Severe Pediatric Guillain-Barre Syndrome after Immunotherapy or Supportive Care
Neurol 52:1494-1497, Graf,W.D.,et al, 1999

Prognostic Factors of Guillain-Barre Syndrome After Intravenous Immunoglobulin or Plasma Exchange?
Neurol 53:598-604, Visser,L.H.,et al, 1999

Intensive Care of the Myasthenic Patient
Neurol 48 (Suppl 5) :S70-S75997., Mayer,S.A., 1997

Chronic Inflammatory Demyelinating Polyradiculoneuropathy in Children
Muscle & Nerve 20:1569-1575997., Simmons,Z.,et al, 1997

Campylobacter Jejuni Infection and Anti-GM1 Antibodies in Guillain-Barre Syndrome
Ann Neurol 40:181-187, Jacobs,B.C.,et al, 1996

Recommendations for Off-Label Use of Intravenously Administered Immunoglobulin Preparations
JAMA 273:1865-1870, Ratko,T.A.,et al, 1995

High-Dose Intravenous Immunoglobulin Therapy in Chronic Progressive Lumbosacral Plexopathy
Neurol 44:248-250, Verma,A.&Bradley,W.G., 1994

Ocular Myasthenia:A Protean Disorder
Survey of Ophthalmology 39:169-210, Weinberg,D.A.,et al, 1994

Intensive Management and Treatment of Severe Guillain-Barre Syndrome
Crit Care Med 21:433-446, Hund,E.F.,et al, 1993

Clinical Uses of Intravenous Immunoglobulins
Ann Int Med 112:278-292, Berkman,S.A.,et al, 1990

High Dose Gammaglobulin for Intractable Childhood Epilepsy
Lancet 2:162-163, Ariizumi,M.,et al, 1983



Showing articles 0 to 45 of 45